

Table S1. The 3 and 5-year DFS and OS are reported for those who achieved greater than 80% RDI for the respective therapeutic versus those who did not exceed 80% RDI.

		3-year DFS (%)		5-year DFS (%)		P value
		≤80%	> 80%	≤80%	>80%	
Capecitabine	RDI	67.4%	65.2%	55.8%	60.9%	0.820
Oxaliplatin	RDI	76.9%	76.8%	72.8%	68.8%	0.868
5-FU	RDI	79.9%	75.2%	77.7%	67.6%	0.512
		3-year OS (%)		5-year OS (%)		P value
		≤80%	> 80%	≤80%	> 80%	
Capecitabine	RDI	79.1%	82.6%	62.8%	73.9%	0.560
Oxaliplatin	RDI	87.7%	84.6%	75.4%	78.6%	0.523
5-FU	RDI	91.1%	83.9%	79.7%	75.0%	0.691




Figure S1. Kaplan–Meier plot of DFS stratified by RDI of capecitabine in patients receiving capecitabine.





Figure S2. Kaplan–Meier plot of DFS stratified by RDI of 5-FU and oxaliplatin in patients receiving FOLFOX.



Number at risk

	0	1	2	3	4	5	6
Capecitabine RDI ≤ 80%	43	41	38	34	32	27	11
Capecitabine RDI > 80%	23	22	22	19	18	17	5

Figure S3. Kaplan–Meier plot of OS stratified by RDI of capecitabine in patients receiving capecitabine.




Figure S4. Kaplan–Meier plot of OS stratified by RDI of 5-FU and oxaliplatin in patients receiving FOLFOX.